Oxygen Biotherapeutics to Present at Aegis Capital Healthcare Conference in Las Vegas on September 27, 2013 Aegis Capital Healthcare Conference 2013 Business Wire MORRISVILLE, N.C. -- September 19, 2013 Oxygen Biotherapeutics, Inc., (NASDAQ: OXBT) a developer of oxygen-carrying therapeutics, announced today that the Company’s Interim CEO, President and CFO Michael Jebsen, will participate in the Aegis Capital Healthcare Conference in Las Vegas from September 25 – 28, 2013. Michael Jebsen is scheduled to present an overview of Oxygen Biotherapeutics to investors on Friday, September 27th at 8:30 am PT. Investors or journalists may request a one-on-one meeting with Oxygen Biotherapeutics’ management by contacting Robert Haag at 1-866-976-IRTH (4784) or email@example.com. Oxygen Biotherapeutics was recently issued a new patent for its PFC-based products for topical delivery to the skin for dermatologic conditions and wound care for indications of psoriasis and pruritus. The Company is currently conducting Phase IIb trials for its proprietary perfluorocarbon (PFC) therapeutic oxygen carrier called Oxycyte® for the treatment of severe non-penetrating traumatic brain injury. The Company’s platform technology addresses multiple healthcare markets valued at well over $1 billion. Oxygen Biotherapeutics maintains research contracts with the U.S. military and owns or exclusively licenses 9 patents issued and pending. About Oxygen Biotherapeutics, Inc. Oxygen Biotherapeutics, Inc. is developing medical products that efficiently deliver oxygen to tissues in the body. The company has developed a proprietary perfluorocarbon (PFC) therapeutic oxygen carrier called Oxycyte^®that is currently in clinical and preclinical studies for intravenous delivery for indications such as traumatic brain injury, decompression sickness and stroke. The company is also developing PFC-based creams and gels for topical delivery to the skin for dermatologic conditions and potentially wound care. In addition, the Company has commercialized its Dermacyte^®line of skin care cosmetics for the anti-aging market. Dermacyte is now out-licensed to Valor Cosmetics of Switzerland. Caution Regarding Forward-Looking Statements This news release contains certain forward-looking statements by the company that involve risks and uncertainties and reflect the company’s judgment as of the date of this release. The forward-looking statements are subject to a number of risks and uncertainties, delays in new product introductions and customer acceptance of these new products, and other risks and uncertainties as described in our filings with the Securities and Exchange Commission, including in the current Form 10-Q filed on September 17, 2013, and our annual report on Form 10-K filed on June 26, 2013, as well as other filings with the SEC. The company disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Contact: Oxygen Biotherapeutics Investor and Media Relations Robert Haag, 1-866-976-IRTH (4784) Managing Director IRTH Communications firstname.lastname@example.org
Oxygen Biotherapeutics to Present at Aegis Capital Healthcare Conference in Las Vegas on September 27, 2013
Press spacebar to pause and continue. Press esc to stop.